|
1
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jorfi S and Inal JM: The role of
microvesicles in cancer progression and drug resistance. Biochem
Soc Trans. 41:293–298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nyga A, Cheema U and Loizidou M: 3D tumour
models: novel in vitro approaches to cancer studies. J Cell Commun
Signal. 5:239–248. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fridman WH, Dieu-Nosjean MC, Pages F,
Cremer I, Damotte D, Sautes-Fridman C and Galon J: The immune
microenvironment of human tumors: general significance and clinical
impact. Cancer Microenviron. 6:117–122. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fennema E, Rivron N, Rouwkema J, van
Blitterswijk C and de Boer J: Spheroid culture as a tool for
creating 3D complex tissues. Trends Biotechnol. 31:108–115. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McMillin DW, Negri JM and Mitsiades CS:
The role of tumour-stromal interactions in modifying drug response:
challenges and opportunities. Nat Rev Drug Discov. 12:217–228.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morin PJ: Drug resistance and the
microenvironment: nature and nurture. Drug Resist Updat. 6:169–172.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wartenberg M, Gronczynska S, Bekhite MM,
Saric T, Niedermeier W, Hescheler J and Sauer H: Regulation of the
multidrug resistance transporter P-glycoprotein in multicellular
prostate tumor spheroids by hyperthermia and reactive oxygen
species. Int J Cancer. 113:229–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamada KM and Cukierman E: Modeling tissue
morphogenesis and cancer in 3D. Cell. 130:601–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horning JL, Sahoo SK, Vijayaraghavalu S,
Dimitrijevic S, Vasir JK, Jain TK, Panda AK and Labhasetwar V: 3-D
tumor model for in vitro evaluation of anticancer drugs. Mol Pharm.
5:849–862. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chitcholtan K, Sykes PH and Evans JJ: The
resistance of intracellular mediators to doxorubicin and cisplatin
are distinct in 3D and 2D endometrial cancer. J Transl Med.
10:382012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee JM, Mhawech-Fauceglia P, Lee N,
Parsanian LC, Lin YG, Gayther SA and Lawrenson K: A
three-dimensional microenvironment alters protein expression and
chemosensitivity of epithelial ovarian cancer cells in vitro. Lab
Invest. 93:528–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Longati P, Jia X, Eimer J, Wagman A, Witt
MR, Rehnmark S, Verbeke C, Toftgard R, Lohr M and Heuchel RL: 3D
pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant
phenotype offering a better model for drug testing. BMC Cancer.
13:952013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yeon SE, No da Y, Lee SH, Nam SW, Oh IH,
Lee J and Kuh HJ: Application of concave microwells to pancreatic
tumor spheroids enabling anticancer drug evaluation in a clinically
relevant drug resistance model. PLoS One. 8:e733452013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hehlgans S, Eke I, Storch K, Haase M,
Baretton GB and Cordes N: Caveolin-1 mediated radioresistance of 3D
grown pancreatic cancer cells. Radiother Oncol. 92:362–370. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nirmalanandhan VS, Duren A, Hendricks P,
Vielhauer G and Sittampalam GS: Activity of anticancer agents in a
three-dimensional cell culture model. Assay Drug Dev Technol.
8:581–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Godugu C, Patel AR, Desai U, Andey T, Sams
A and Singh M: AlgiMatrix™ based 3D cell culture system as an
in-vitro tumor model for anticancer studies. PLoS One.
8:e537082013.
|
|
18
|
Lombardi L, Gebbia V, Silvestris N, Testa
A, Colucci G and Maiello E: Adjuvant therapy in colon cancer.
Oncology. 77:50–56. 2009. View Article : Google Scholar
|
|
19
|
Neuman HB, Park J and Weiser MR:
Randomized clinical trials in colon cancer. Surg Oncol Clin N Am.
19:183–204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kinoshita M, Kodera Y, Hibi K, Nakayama G,
Inoue T, Ohashi N, Ito Y, Koike M, Fujiwara M and Nakao A: Gene
expression profile of 5-fluorouracil metabolic enzymes in primary
colorectal cancer: potential as predictive parameters for response
to fluorouracil-based chemotherapy. Anticancer Res. 27:851–856.
2007.
|
|
21
|
Zhang N, Yin Y, Xu SJ and Chen WS:
5-Fluorouracil: mechanisms of resistance and reversal strategies.
Molecules. 13:1551–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reddy SB and Williamson SK: Tirapazamine:
a novel agent targeting hypoxic tumor cells. Expert Opin Investig
Drugs. 18:77–87. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
LaRue KE, Khalil M and Freyer JP:
Microenvironmental regulation of proliferation in multicellular
spheroids is mediated through differential expression of
cyclin-dependent kinase inhibitors. Cancer Res. 64:1621–1631. 2004.
View Article : Google Scholar
|
|
24
|
Chari NS, Pinaire NL, Thorpe L, Medeiros
LJ, Routbort MJ and McDonnell TJ: The p53 tumor suppressor network
in cancer and the therapeutic modulation of cell death. Apoptosis.
14:336–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakamura T, Kato Y, Fuji H, Horiuchi T,
Chiba Y and Tanaka K: E-cadherin-dependent intercellular adhesion
enhances chemoresistance. Int J Mol Med. 12:693–700.
2003.PubMed/NCBI
|
|
26
|
Tomasini R, Mak TW and Melino G: The
impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol.
18:244–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hafsi S, Pezzino FM, Candido S, Ligresti
G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M: Gene
alterations in the PI3K/PTEN/AKT pathway as a mechanism of
drug-resistance (Review). Int J Oncol. 40:639–644. 2012.PubMed/NCBI
|
|
28
|
Lee EC, Lee YS, Park NH, So KS, Chun YJ
and Kim MY: Ceramide induces apoptosis and growth arrest of human
glioblastoma cells by inhibiting akt signaling pathways. Biomol
Therap. 19:21–26. 2011. View Article : Google Scholar
|
|
29
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee CS, Kim KL, Jang JH, Choi YS, Suh PG
and Ryu SH: The roles of phospholipase D in EGFR signaling. Biochim
Biophys Acta. 1791:862–868. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kang DW, Choi KY and Min do S:
Phospholipase D meets Wnt signaling: a new target for cancer
therapy. Cancer Res. 71:293–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oliemuller E, Pelaez R, Garasa S, Pajares
MJ, Agorreta J, Pio R, Montuenga LM, Teijeira A, Llanos S and
Rouzaut A: Phosphorylated tubulin adaptor protein CRMP-2 as
prognostic marker and candidate therapeutic target for NSCLC. Int J
Cancer. 132:1986–1995. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Barkley LR, Song IY, Zou Y and Vaziri C:
Reduced expression of GINS complex members induces hallmarks of
pre-malignancy in primary untransformed human cells. Cell Cycle.
8:1577–1588. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Obama K, Ura K, Satoh S, Nakamura Y and
Furukawa Y: Up-regulation of PSF2, a member of the GINS
multiprotein complex, in intrahepatic cholangiocarcinoma. Oncol
Rep. 14:701–706. 2005.PubMed/NCBI
|
|
36
|
Kim H, Kang HJ, You KT, Kim SH, Lee KY,
Kim TI, Kim C, Song SY, Kim HJ, Lee C, et al: Suppression of human
selenium-binding protein 1 is a late event in colorectal
carcinogenesis and is associated with poor survival. Proteomics.
6:3466–3476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang S, Li F, Younes M, Liu H, Chen C and
Yao Q: Reduced selenium-binding protein 1 in breast cancer
correlates with poor survival and resistance to the
anti-proliferative effects of selenium. PLoS One. 8:e637022013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li T, Yang W, Li M, Byun DS, Tong C,
Nasser S, Zhuang M, Arango D, Mariadason JM and Augenlicht LH:
Expression of selenium-binding protein 1 characterizes intestinal
cell maturation and predicts survival for patients with colorectal
cancer. Mol Nutr Food Res. 52:1289–1299. 2008. View Article : Google Scholar : PubMed/NCBI
|
